Tci Wealth Advisors, Inc. Corcept Therapeutics Inc Transaction History

Tci Wealth Advisors, Inc.

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 06, 2023	BUY	$19.95 - $29.96 $3,112 - $4,673	156 Added 28.16%	710 $14,000
Q2 2022 Jul 19, 2022	BUY	$17.33 - $25.3 $381 - $556	22 Added 4.14%	554 $13,000
Q4 2021 Jan 24, 2022	BUY	$17.1 - $23.34 $1,402 - $1,913	82 Added 18.22%	532 $11,000
Q3 2021 Oct 29, 2021	BUY	$19.68 - $22.53 $4,368 - $5,001	222 Added 97.37%	450 $9,000
Q2 2021 Aug 02, 2021	SELL	$19.97 - $24.43 $1,537 - $1,881	-77 Reduced 25.25%	228 $5,000
Q1 2021 Apr 29, 2021	BUY	$23.49 - $30.56 $4,580 - $5,959	195 Added 177.27%	305 $7,000
Q1 2020 Apr 14, 2020	BUY	$10.11 - $14.04 $353 - $491	35 Added 46.67%	110 $1,000
Q1 2019 Apr 11, 2019	SELL	$10.03 - $15.71 $521 - $816	-52 Reduced 40.94%	75 $1,000
Q4 2018 Jan 17, 2019	BUY	$11.29 - $17.19 $587 - $893	52 Added 69.33%	127 $2,000
Q2 2018 Jul 27, 2018	SELL	$15.3 - $19.69 $734 - $945	-48 Reduced 39.02%	75 $1,000
Q1 2018 Apr 30, 2018	BUY	$14.59 - $25.5 $700 - $1,224	48 Added 64.0%	123 $2,000
Q2 2017 Aug 10, 2017	BUY	N/A	75	75 $1,000

403

84.3M

1.04M

1.33M

Ticker CORT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 107,105,000
Market Cap $6.81B
Description
Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients ...

Get notified when there are updates to the investment portfolio of Tci Wealth Advisors, Inc., based on Form 13F filings with the SEC.

Stay updated on Tci Wealth Advisors, Inc. with notifications on news.